US 12,221,433 B2
Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
Anne-Marie Beausoleil, South San Francisco, CA (US); and Ryan Hudson, South San Francisco, CA (US)
Assigned to Unity Biotechnology, Inc., South San Francisco, CA (US)
Filed by Unity Biotechnology, Inc., South San Francisco, CA (US)
Filed on Jun. 3, 2021, as Appl. No. 17/338,368.
Application 17/338,368 is a continuation of application No. 16/888,197, filed on May 29, 2020, abandoned.
Application 16/888,197 is a continuation of application No. 16/446,360, filed on Jun. 19, 2019, granted, now 10,717,722, issued on Jul. 21, 2020.
Application 16/446,360 is a continuation of application No. PCT/US2019/037067, filed on Jun. 13, 2019.
Claims priority of provisional application 62/684,681, filed on Jun. 13, 2018.
Prior Publication US 2022/0017485 A1, Jan. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/12 (2006.01); A61P 9/10 (2006.01); A61P 11/00 (2006.01); A61P 27/00 (2006.01); A61P 35/00 (2006.01); C07D 401/10 (2006.01); C07D 401/14 (2006.01); C07D 403/10 (2006.01); C07F 9/6509 (2006.01)
CPC C07D 401/12 (2013.01) [A61P 9/10 (2018.01); A61P 11/00 (2018.01); A61P 27/00 (2018.01); A61P 35/00 (2018.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 403/10 (2013.01); C07F 9/650952 (2013.01)] 1 Claim
 
1. A pharmaceutical composition comprising a compound:

OG Complex Work Unit Chemistry
and one or more pharmaceutically acceptable excipients.